Additionally, WIF1 has been found to enhance chemosensitivity of prostate cancer to certain anticancer drugs, including paclitaxel and etoposide, suggesting a potential role for WIF1 in improving treatment outcomes [81]. This evidence concerns the gene WIF1 and prostate carcinoma.